What does this research mean for the field?

Survivors of pediatric CNS tumors face a high cumulative burden of multisystem late effects, necessitating personalized, multidisciplinary, and risk-stratified survivorship care to optimize long-term quality of life. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To summarize the multisystem late toxicities, surveillance guidelines, and emerging survivorship challenges associated with multimodal therapy in pediatric central nervous system tumor survivors.

September 14, 2026Expert Review of Anticancer Therapy

Overcoming emerging challenges in childhood cancer survivorship: a spotlight on pediatric CNS tumors

View Full Paper

Ask AI

Bookmark

Authors

ESElisabetta Schiavello VBVeronica Biassoni ONOlga Nigro

Discussion

Member takes

Overview

Narrative review reveals high burden of multisystem late effects in pediatric central nervous system tumor survivors, highlighting the need for risk-adapted lifelong care.

Key Points

To summarize the multisystem late toxicities, surveillance guidelines, and emerging survivorship challenges associated with multimodal therapy in pediatric central nervous system tumor survivors.
Reviewed clinical evidence detailing organ-specific late toxicities associated with surgery, radiotherapy, chemotherapy, and novel targeted agents.
Synthesized current surveillance recommendations, intervention strategies, and risk-adapted models for transitioning survivors into adult healthcare systems.
Pediatric central nervous system tumor survivors experience substantial long-term morbidity, including endocrine deficiency, impaired fertility, neurocognitive decline, secondary malignancies, ototoxicity, and cardiovascular disorders.
Emerging targeted therapies and immunotherapies present novel, incompletely defined late toxicities that require updated, individualized monitoring protocols.
Comprehensive, multidisciplinary survivorship clinics and structured transition programs are critical to improving quality of survival alongside curative outcomes.

Cite This Study

Schiavello et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3580926e14a848b239e https://doi.org/10.1080/14737140.2026.2730176

View Full Paper

Ask AI

Bookmark

September 14, 2026Expert Review of Anticancer Therapy

Overcoming emerging challenges in childhood cancer survivorship: a spotlight on pediatric CNS tumors

View Full Paper

Ask AI

Bookmark

Authors

ESElisabetta Schiavello VBVeronica Biassoni ONOlga Nigro

Discussion

Member takes

Overview

Narrative review reveals high burden of multisystem late effects in pediatric central nervous system tumor survivors, highlighting the need for risk-adapted lifelong care.

Key Points

To summarize the multisystem late toxicities, surveillance guidelines, and emerging survivorship challenges associated with multimodal therapy in pediatric central nervous system tumor survivors.
Reviewed clinical evidence detailing organ-specific late toxicities associated with surgery, radiotherapy, chemotherapy, and novel targeted agents.
Synthesized current surveillance recommendations, intervention strategies, and risk-adapted models for transitioning survivors into adult healthcare systems.
Pediatric central nervous system tumor survivors experience substantial long-term morbidity, including endocrine deficiency, impaired fertility, neurocognitive decline, secondary malignancies, ototoxicity, and cardiovascular disorders.
Emerging targeted therapies and immunotherapies present novel, incompletely defined late toxicities that require updated, individualized monitoring protocols.
Comprehensive, multidisciplinary survivorship clinics and structured transition programs are critical to improving quality of survival alongside curative outcomes.

Cite This Study

Schiavello et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b3580926e14a848b239e https://doi.org/10.1080/14737140.2026.2730176

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark